Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.56 | N/A | +17.18% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.56 | N/A | +17.18% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook, emphasizing the importance of their ongoing projects. They did not provide new guidance, reflecting uncertainty.
Management did not provide specific revenue guidance for the upcoming quarters.
The focus remains on advancing their pipeline despite current challenges.
Nektar Therapeutics reported a wider-than-expected loss per share but did not disclose revenue figures. The stock fell by 2.37% following the report, likely due to the lack of guidance and concerns over future performance. Investors may be cautious as the company navigates its pipeline and market challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CONSOLIDATED EDISON
Nov 4, 2019